Skip to main content
SpringerLink
Log in

Transvenous or subcutaneous implantable cardioverter defibrillator: a review to aid decision-making

  • Published:
Journal of Interventional Cardiac Electrophysiology Aims and scope Submit manuscript

Abstract

The implantable cardioverter-defibrillator (ICD) is a proven treatment for preventing sudden cardiac death. Transvenous leads are associated with significant mortality and morbidity, and the subcutaneous ICD (S-ICD) addresses this. However, it is not without limitations, in particular the absence of anti-tachycardia pacing. The decision of which device is most suitable for an individual patient is often complex. Here, we review the relative merits and weaknesses of both the transvenous and S-ICD. We summarise the available evidence for each device in particular patient cohorts, namely: ischaemic and non-ischaemic cardiomyopathy, idiopathic ventricular fibrillation, Brugada syndrome, long QT syndrome, arrhythmogenic right ventricular cardiomyopathy, and hypertrophic cardiomyopathy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36:2793–867.

    Article  PubMed  Google Scholar 

  2. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;20(352):225–37.

    Article  Google Scholar 

  3. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83.

    Article  PubMed  Google Scholar 

  4. Goldenberg I, Gillespie J, Moss AJ, et al. Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. Circulation. 2010;122:1265–71.

    Article  PubMed  Google Scholar 

  5. Alter P, Waldhans S, Plachta E, et al. Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. Pacing Clin Electrophysiol. 2005;28:926–32.

    Article  PubMed  Google Scholar 

  6. Kleemann T, Becker T, Doenges K, et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years. Circulation. 2007;115:2474–80.

    Article  PubMed  Google Scholar 

  7. Maisel WH, Kramer DB. Implantable cardioverter-defibrillator lead performance. Circulation. 2008;117:2721–3.

    Article  PubMed  Google Scholar 

  8. Atallah J, Erickson CC, Cecchin F, et al. Multi-institutional study of implantable defibrillator lead performance in children and young adults: results of the Pediatric Lead Extractability and Survival Evaluation (PLEASE) study. Circulation. 2013;127:2393–402.

    Article  PubMed  Google Scholar 

  9. Borleffs CJ, van Erven L, van Bommel RJ, et al. Risk of failure of transvenous implantable cardioverter-defibrillator leads. Circ Arrhythm Electrophysiol. 2009;2:411–6.

    Article  PubMed  Google Scholar 

  10. Knops RE, OldeNordkamp LRA, Delnoy P-PHM, et al. Subcutaneous or transvenous defibrillator therapy. New England J Med. 2020;383:526–36.

    Article  Google Scholar 

  11. Maytin M, Jones SO, Epstein LM. Long-term mortality after transvenous lead extraction. Circ Arrhythm Electrophysiol. 2012;5:252–7.

    Article  CAS  PubMed  Google Scholar 

  12. Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation. 2013;128:944–53.

    Article  PubMed  Google Scholar 

  13. Burke MC, Gold MR, Knight BP, et al. Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry. J Am Coll Cardiol. 2015;65:1605–15.

    Article  PubMed  Google Scholar 

  14. Ferrari P, Giofrè F, De Filippo P. Intermuscular pocket for subcutaneous implantable cardioverter defibrillator: Single-center experience. J Arrhythm. 2016;32:223–6.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Smietana J, Frankel DS, Serletti JM, et al. Subserratus implantation of the subcutaneous implantable cardioverter-defibrillator. Heart Rhythm. 2021;18:1799–804.

    Article  PubMed  Google Scholar 

  16. Olde Nordkamp LR, Warnaars JL, Kooiman KM, et al. Which patients are not suitable for a subcutaneous ICD: incidence and predictors of failed QRS-T-wave morphology screening. J Cardiovasc Electrophysiol. 2014;25:494–9.

    Article  PubMed  Google Scholar 

  17. Gold MR, Theuns DA, Knight BP, et al. Head-to-head comparison of arrhythmia discrimination performance of subcutaneous and transvenous ICD arrhythmia detection algorithms: the START study. J Cardiovasc Electrophysiol. 2012;23:359–66.

    Article  PubMed  Google Scholar 

  18. Mandrola J, Enache B, Weiss R, et al. Point/counterpoint on halting implantation of the subcutaneous ICD. JACC: Clin Electrophysiol. 2021;7:685–9.

    Google Scholar 

  19. Killingsworth CR, Melnick SB, Litovsky SH, et al. Evaluation of acute cardiac and chest wall damage after shocks with a subcutaneous implantable cardioverter defibrillator in Swine. Pacing Clin Electrophysiol. 2013;36:1265–72.

    PubMed  PubMed Central  Google Scholar 

  20. Pothineni NVK, Cherian T, Patel N, et al. Subcutaneous implantable cardioverter-defibrillator explantation-a single tertiary center experience. J Innovations Cardiac Rhythm Manag. 2022;13:4947–53.

    Article  Google Scholar 

  21. U.S. Food and Drug Administration. “Boston Scientific Recalls EMBLEM S-ICD Subcutaneous Electrode (Model 3501) Due to Risk of Fractures”. 2021. Available at: https://www.fda.gov/medical-devices/postmarket-requirements-devices/recalls-corrections-and-removals-devices. Accessed April 4, 2021. .

  22. Tjong FV, Brouwer TF, Kooiman KM, et al. Communicating antitachycardia pacing-enabled leadless pacemaker and subcutaneous implantable defibrillator. J Am Coll Cardiol. 2016;67:1865–6.

    Article  PubMed  Google Scholar 

  23. Sidhu BS, Gould J, Porter B, et al. Completely Leadless Cardiac Resynchronization Defibrillator System. JACC Clin Electrophysiol. 2020;6:588–9.

    Article  PubMed  Google Scholar 

  24. Knops RE, Olde Nordkamp LRA, Delnoy PHM, et al. Subcutaneous or Transvenous Defibrillator Therapy. N Engl J Med. 2020;383:526–36.

    Article  PubMed  Google Scholar 

  25. Kolodziejczak M, Andreotti F, Kowalewski M, et al. Implantable cardioverter-defibrillators for primary prevention in patients with ischemic or nonischemic cardiomyopathy: a systematic review and meta-analysis. Ann Intern Med. 2017;167:103–11.

    Article  PubMed  Google Scholar 

  26. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21:2071–8.

    Article  CAS  PubMed  Google Scholar 

  27. Olde Nordkamp LR, Dabiri Abkenari L, Boersma LV, et al. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort. J Am Coll Cardiol. 2012;60:1933–9.

    Article  PubMed  Google Scholar 

  28. Lambiase PD, Barr C, Theuns DA, et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J. 2014;35:1657–65.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Gold MR, Lambiase PD, El-Chami MF, et al. Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation. 2021;143:7–17.

    Article  PubMed  Google Scholar 

  30. Antiarrhythmics versus Implantable Defibrillators I. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576–83.

    Article  Google Scholar 

  31. G. Gshasj. PO01–32: incidence of pacemaker implantation in SCD-HeFT: are single- chamber ICDs enough in heart failure (abstr)?. Heart Rhythm 2014;11.

  32. Bloch Thomsen PE, Jons C, Raatikainen MJ, et al. Long-term recording of cardiac arrhythmias with an implantable cardiac monitor in patients with reduced ejection fraction after acute myocardial infarction: the Cardiac Arrhythmias and Risk Stratification After Acute Myocardial Infarction (CARISMA) study. Circulation. 2010;122:1258–64.

    Article  PubMed  Google Scholar 

  33. Prinzen FW, Vernooy K, Auricchio A. Cardiac resynchronization therapy: state-of-the-art of current applications, guidelines, ongoing trials, and areas of controversy. Circulation. 2013;128:2407–18.

    Article  PubMed  Google Scholar 

  34. Daubert JC, Leclercq C, Mabo P. Cardiac resynchronization therapy in combination with implantable cardioverter-defibrillator. Europace. 2009;11(Suppl 5):v87-92.

    Article  PubMed  Google Scholar 

  35. Sweeney MO, Sherfesee L, DeGroot PJ, et al. Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm. 2010;7:353–60.

    Article  PubMed  Google Scholar 

  36. Wathen MS, DeGroot PJ, Sweeney MO, et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation. 2004;110:2591–6.

    Article  PubMed  Google Scholar 

  37. Wilkoff BL, Ousdigian KT, Sterns LD, et al. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial. J Am Coll Cardiol. 2006;48:330–9.

    Article  PubMed  Google Scholar 

  38. Wilkoff BL, Williamson BD, Stern RS, et al. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol. 2008;52:541–50.

    Article  PubMed  Google Scholar 

  39. Streitner F, Kuschyk J, Dietrich C, et al. Comparison of ventricular tachyarrhythmia characteristics in patients with idiopathic dilated or ischemic cardiomyopathy and defibrillators implanted for primary prevention. Clin Cardiol. 2011;34:604–9.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Moss AJ, Schuger C, Beck CA, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012;367:2275–83.

    Article  CAS  PubMed  Google Scholar 

  41. Crijns HJ, Wiesfeld AC, Posma JL, et al. Favourable outcome in idiopathic ventricular fibrillation with treatment aimed at prevention of high sympathetic tone and suppression of inducible arrhythmias. Br Heart J. 1995;74:408–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. OldeNordkamp LR, Wilde AA, Tijssen JG, et al. The ICD for primary prevention in patients with inherited cardiac diseases: indications, use, and outcome: a comparison with secondary prevention. Circ Arrhythm Electrophysiol. 2013;6:91–100.

    Article  Google Scholar 

  43. Haissaguerre M, Derval N, Sacher F, et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med. 2008;358:2016–23.

    Article  CAS  PubMed  Google Scholar 

  44. Conte G, Kawabata M, de Asmundis C, et al. High rate of subcutaneous implantable cardioverter-defibrillator sensing screening failure in patients with Brugada syndrome: a comparison with other inherited primary arrhythmia syndromes. Europace. 2017;

  45. Sacher F, Probst V, Maury P, et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study-part 2. Circulation. 2013;128:1739–47.

    Article  PubMed  Google Scholar 

  46. Rodriguez-Manero M, Sacher F, de Asmundis C, et al. Monomorphic ventricular tachycardia in patients with Brugada syndrome: a multicenter retrospective study. Heart Rhythm. 2016;13:669–82.

    Article  PubMed  Google Scholar 

  47. Conte G, Dea C, Sieira J, et al. Clinical characteristics, management, and prognosis of elderly patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2014;25:514–9.

    Article  PubMed  Google Scholar 

  48. Conte G, Dewals W, Sieira J, et al. Drug-induced brugada syndrome in children: clinical features, device-based management, and long-term follow-up. J Am Coll Cardiol. 2014;63:2272–9.

    Article  PubMed  Google Scholar 

  49. Bordachar P, Reuter S, Garrigue S, et al. Incidence, clinical implications and prognosis of atrial arrhythmias in Brugada syndrome. Eur Heart J. 2004;25:879–84.

    Article  PubMed  Google Scholar 

  50. van den Berg MP, Wilde AA, Viersma TJW, et al. Possible bradycardic mode of death and successful pacemaker treatment in a large family with features of long QT syndrome type 3 and Brugada syndrome. J Cardiovasc Electrophysiol. 2001;12:630–6.

    Article  PubMed  Google Scholar 

  51. Sacher F, Probst V, Iesaka Y, et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study. Circulation. 2006;114:2317–24.

    Article  PubMed  Google Scholar 

  52. Sarkozy A, Boussy T, Kourgiannides G, et al. Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome. Eur Heart J. 2007;28:334–44.

    Article  PubMed  Google Scholar 

  53. OldeNordkamp LR, Postema PG, Knops RE, et al. Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: a systematic review and meta-analysis of inappropriate shocks and complications. Heart Rhythm. 2016;13:443–54.

    Article  Google Scholar 

  54. Morita H, Kusano-Fukushima K, Nagase S, et al. Atrial fibrillation and atrial vulnerability in patients with Brugada syndrome. J Am Coll Cardiol. 2002;40:1437–44.

    Article  PubMed  Google Scholar 

  55. Francis J, Antzelevitch C. Atrial fibrillation and Brugada syndrome. J Am Coll Cardiol. 2008;51:1149–53.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Hauck M, Bauer A, Voss F, et al. “Home monitoring” for early detection of implantable cardioverter-defibrillator failure: a single-center prospective observational study. Clin Res Cardiol. 2009;98:19–24.

    Article  PubMed  Google Scholar 

  57. Sacher F, Probst V, Bessouet M, et al. Remote implantable cardioverter defibrillator monitoring in a Brugada syndrome population. Europace. 2009;11:489–94.

    Article  PubMed  Google Scholar 

  58. Veltmann C, Kuschyk J, Schimpf R, et al. Prevention of inappropriate ICD shocks in patients with Brugada syndrome. Clin Res Cardiol. 2010;99:37–44.

    Article  PubMed  Google Scholar 

  59. Basu-Ray I, Liu J, Jia X, et al. Subcutaneous versus transvenous implantable defibrillator therapy: a meta-analysis of case-control studies. JACC Clin Electrophysiol. 2017;26(3):1475–83.

    Article  Google Scholar 

  60. Conte G, Regoli F, Moccetti T, et al. Subcutaneous implantable cardioverter-defibrillator and drug-induced Brugada syndrome: the importance of repeat morphology analysis during ajmaline challenge. Eur Heart J. 2016;37:1498.

    Article  PubMed  Google Scholar 

  61. Lambiase PD, Eckardt L, Theuns DA, et al. Evaluation of subcutaneous implantable cardioverter-defibrillator performance in patients with ion channelopathies from the EFFORTLESS cohort and comparison with a meta-analysis of transvenous ICD outcomes. Heart Rhythm. 2020;1:326–35.

    Article  Google Scholar 

  62. Schwartz PJ. Idiopathic long QT syndrome: progress and questions. Am Heart J. 1985;109:399–411.

    Article  CAS  PubMed  Google Scholar 

  63. Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation. 1991;84:1136–44.

    Article  CAS  PubMed  Google Scholar 

  64. Schwartz PJ, Locati EH, Moss AJ, et al. Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome. A worldwide report. Circulation. 1991;84:503–11.

    Article  CAS  PubMed  Google Scholar 

  65. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation. 2000;101:616–23.

    Article  CAS  PubMed  Google Scholar 

  66. Groh WJ, Silka MJ, Oliver RP, et al. Use of implantable cardioverter-defibrillators in the congenital long QT syndrome. Am J Cardiol. 1996;78:703–6.

    Article  CAS  PubMed  Google Scholar 

  67. Monnig G, Kobe J, Loher A, et al. Implantable cardioverter-defibrillator therapy in patients with congenital long-QT syndrome: a long-term follow-up. Heart Rhythm. 2005;2:497–504.

    Article  PubMed  Google Scholar 

  68. Moss AJ, Liu JE, Gottlieb S, et al. Efficacy of permanent pacing in the management of high-risk patients with long QT syndrome. Circulation. 1991;84:1524–9.

    Article  CAS  PubMed  Google Scholar 

  69. Mazzanti A, Ng K, Faragli A, et al. Arrhythmogenic right ventricular cardiomyopathy: clinical course and predictors of arrhythmic risk. J Am Coll Cardiol. 2016;68:2540–50.

    Article  PubMed  Google Scholar 

  70. Schinkel AF. Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications. Circ Arrhythm Electrophysiol. 2013;6:562–8.

    Article  PubMed  Google Scholar 

  71. Bhonsale A, James CA, Tichnell C, et al. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol. 2011;58:1485–96.

    Article  PubMed  Google Scholar 

  72. Watanabe H, Chinushi M, Izumi D, et al. Decrease in amplitude of intracardiac ventricular electrogram and inappropriate therapy in patients with an implantable cardioverter defibrillator. Int Heart J. 2006;47:363–70.

    Article  PubMed  Google Scholar 

  73. Link MS, Laidlaw D, Polonsky B, et al. Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, characteristics, and treatment. J Am Coll Cardiol. 2014;64:119–25.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Zorzi A, ElMaghawry M, Rigato I, et al. Exercise-induced normalization of right precordial negative T waves in arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol. 2013;112:411–5.

    Article  PubMed  Google Scholar 

  75. Migliore FBEZACD. Subcutaneous implantable cardioverter-defibrillator and arrhythmogenic right ventricular cardiomyopathy: the importance of repeat ecg screening during exercise test. Jacc: Clin Electrophysiol. 2017;3:785–6.

    Google Scholar 

  76. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000;102:858–64.

    Article  CAS  PubMed  Google Scholar 

  77. McKenna W, Harris L, Deanfield J. Syncope in hypertrophic cardiomyopathy. Br Heart J. 1982;47:177–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Nicod P, Polikar R, Peterson KL. Hypertrophic cardiomyopathy and sudden death. N Engl J Med. 1988;318:1255–7.

    Article  CAS  PubMed  Google Scholar 

  79. Schinkel AF, Vriesendorp PA, Sijbrands EJ, et al. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis. Circ Heart Fail. 2012;5:552–9.

    Article  CAS  PubMed  Google Scholar 

  80. Maron BJ, Maron MS. Hypertrophic cardiomyopathy in childhood: the gradient is not the disease. Excessive use of experimental invasive interventions. J Am Coll Cardiol. 2013;61:210–1.

    Article  PubMed  Google Scholar 

  81. Lambiase PD, Gold MR, Hood M, et al. Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. Heart Rhythm. 2016;13:1066–74.

    Article  PubMed  Google Scholar 

  82. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342:365–73.

    Article  CAS  PubMed  Google Scholar 

  83. Vriesendorp PA, Schinkel AF, Van Cleemput J, et al. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications. Am Heart J. 2013;166:496–502.

    Article  PubMed  Google Scholar 

  84. O’Mahony C, Lambiase PD, Rahman SM, et al. The relation of ventricular arrhythmia electrophysiological characteristics to cardiac phenotype and circadian patterns in hypertrophic cardiomyopathy. Europace. 2012;14:724–33.

    Article  PubMed  Google Scholar 

  85. Task/Force Authors m, Elliott PM, Anastasakis A, et al. 2014SC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology ESC. Eur Heart J 14. 2014;35:2733–79.

    Article  Google Scholar 

  86. Maurizi N, Olivotto I, Olde Nordkamp LR, et al. Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy. Heart Rhythm. 2016;13:457–63.

    Article  PubMed  Google Scholar 

  87. Brisben AJ, Burke MC, Knight BP, et al. A new algorithm to reduce inappropriate therapy in the S-ICD system. J Cardiovasc Electrophysiol. 2015;26:417–23.

    Article  PubMed  Google Scholar 

  88. Da Costa SS, ScalabriniNeto A, Costa R, et al. Incidence and risk factors of upper extremity deep vein lesions after permanent transvenous pacemaker implant: a 6-month follow-up prospective study. Pacing Clin Electrophysiol. 2002;25:1301–6.

    Article  PubMed  Google Scholar 

  89. Boersma L, Burke MC, Neuzil P, et al. Infection and mortality after implantation of a subcutaneous ICD after transvenous ICD extraction. Heart Rhythm. 2016;13:157–64.

    Article  PubMed  Google Scholar 

  90. Saad TF, Hentschel DM, Koplan B, et al. Cardiovascular implantable electronic device leads in CKD and ESRD patients: review and recommendations for practice. Semin Dial. 2013;26:114–23.

    Article  PubMed  Google Scholar 

  91. Brunner MP, Cronin EM, Duarte VE, et al. Clinical predictors of adverse patient outcomes in an experience of more than 5000 chronic endovascular pacemaker and defibrillator lead extractions. Heart Rhythm. 2014;11:799–805.

    Article  PubMed  Google Scholar 

  92. Koman E, Gupta A, Subzposh F, et al. Outcomes of subcutaneous implantable cardioverter-defibrillator implantation in patients on hemodialysis. J Interv Card Electrophysiol. 2016;45:219–23.

    Article  PubMed  Google Scholar 

  93. M S, Leon AR, Merchant FM. E-CMFLMKHMCMHMGALJPADDL. come of subcutaneous implantable cardioverter defibrillator implantation in patients with end stage renal disease on dialysis. J Cardiovasc Electrophysiol. 2015;26:900–4.

    Article  Google Scholar 

  94. Sherrid MV, Daubert JP. Risks and challenges of implantable cardioverter-defibrillators in young adults. Prog Cardiovasc Dis. 2008;51:237–63.

    Article  PubMed  Google Scholar 

  95. Sears SF, St Amant JB, Zeigler V. Psychosocial considerations for children and young adolescents with implantable cardioverter defibrillators: an update. Pacing Clin Electrophysiol. 2009;32(Suppl 2):S80-82.

    Article  PubMed  Google Scholar 

  96. Griksaitis MJ, Rosengarten JA, Gnanapragasam JP, et al. Implantable cardioverter defibrillator therapy in paediatric practice: a single-centre UK experience with focus on subcutaneous defibrillation. Europace. 2013;15:523–30.

    Article  PubMed  Google Scholar 

  97. Pettit SJ, McLean A, Colquhoun I, et al. Clinical experience of subcutaneous and transvenous implantable cardioverter defibrillators in children and teenagers. Pacing Clin Electrophysiol. 2013;36:1532–8.

    Article  PubMed  Google Scholar 

  98. Sarubbi B, Colonna D, Correra A, et al. Subcutaneous implantable cardioverter defibrillator in children and adolescents: results from the S-ICD “Monaldi care” registry. J Interv Card Electrophysiol. 2022;63:283–93.

    Article  PubMed  Google Scholar 

  99. Boriani G, Ritter P, Biffi M, et al. Battery drain in daily practice and medium-term projections on longevity of cardioverter-defibrillators: an analysis from a remote monitoring database. Europace. 2016;18:1366–73.

    Article  PubMed  PubMed Central  Google Scholar 

  100. O’Mahony C, Lambiase PD, Quarta G, et al. The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. Heart. 2012;98:116–25.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

    Milena Leo, Alexander J. Sharp, Andre Briosa e Gala, Michael T. B. Pope & Timothy R. Betts

Authors
  1. Milena Leo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander J. Sharp
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andre Briosa e Gala
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael T. B. Pope
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Timothy R. Betts
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander J. Sharp.

Ethics declarations

Ethics approval

Not applicable.

Informed consent

Not applicable.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leo, M., Sharp, A.J., Gala, A.B.e. et al. Transvenous or subcutaneous implantable cardioverter defibrillator: a review to aid decision-making. J Interv Card Electrophysiol (2022). https://doi.org/10.1007/s10840-022-01299-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10840-022-01299-6

Keywords

Search

Navigation